Pharmacotherapy for treating metastatic clear cell renal cell carcinoma

Camillo Porta, Silvia Chiellino, Alessandra Ferrari, Sara Mariucci, Wanda Liguigli

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which benefited very few patients, at the expenses of high toxicities) to the present era of targeted agents and novel immunotherapeutics, greatly improving the prognosis of our patients. Areas covered: Here we have reviewed the present status of the medical treatment of metastatic RCC. To do this, we interrogated the Medline database, as well as the proceedings of the main Oncological and Urological conferences for the relevant trials coducted so far. Expert opinion: Despite all the advances made in these relatively few years, further improvements are needed, since none of the available agents proved able to cure even a sigle metastatic RCC patient. In particular, advances are awaited from the results of ongoing trial of combinations of different immune checkpoint inhibitors and of immune checkpoint inhibitors with anti-VEGF/VEGFRs agents. Furthermore, a better understanding of the molecular escape pathways used by the tumor to overcome VEGFR blockade or immune activation will hopefully bring soon to the clinic more active, tailored treatments, to be used in second line and beyond.

Original languageEnglish
Pages (from-to)205-216
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number2
DOIs
Publication statusPublished - Jan 22 2017

Fingerprint

Renal Cell Carcinoma
Drug Therapy
Expert Testimony
Immunotherapy
Vascular Endothelial Growth Factor A
Therapeutics
Databases
Cytokines
Clear-cell metastatic renal cell carcinoma
Neoplasms

Keywords

  • Clear cell renal cell carcinoma
  • immune checkpoint inhibitors
  • metastatic disease
  • mTOR inhibitors
  • pharmacotherapy
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. / Porta, Camillo; Chiellino, Silvia; Ferrari, Alessandra; Mariucci, Sara; Liguigli, Wanda.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 2, 22.01.2017, p. 205-216.

Research output: Contribution to journalReview article

Porta, Camillo ; Chiellino, Silvia ; Ferrari, Alessandra ; Mariucci, Sara ; Liguigli, Wanda. / Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. In: Expert Opinion on Pharmacotherapy. 2017 ; Vol. 18, No. 2. pp. 205-216.
@article{961f12d955c545d98c47b1724c80a0d7,
title = "Pharmacotherapy for treating metastatic clear cell renal cell carcinoma",
abstract = "Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which benefited very few patients, at the expenses of high toxicities) to the present era of targeted agents and novel immunotherapeutics, greatly improving the prognosis of our patients. Areas covered: Here we have reviewed the present status of the medical treatment of metastatic RCC. To do this, we interrogated the Medline database, as well as the proceedings of the main Oncological and Urological conferences for the relevant trials coducted so far. Expert opinion: Despite all the advances made in these relatively few years, further improvements are needed, since none of the available agents proved able to cure even a sigle metastatic RCC patient. In particular, advances are awaited from the results of ongoing trial of combinations of different immune checkpoint inhibitors and of immune checkpoint inhibitors with anti-VEGF/VEGFRs agents. Furthermore, a better understanding of the molecular escape pathways used by the tumor to overcome VEGFR blockade or immune activation will hopefully bring soon to the clinic more active, tailored treatments, to be used in second line and beyond.",
keywords = "Clear cell renal cell carcinoma, immune checkpoint inhibitors, metastatic disease, mTOR inhibitors, pharmacotherapy, tyrosine kinase inhibitors",
author = "Camillo Porta and Silvia Chiellino and Alessandra Ferrari and Sara Mariucci and Wanda Liguigli",
year = "2017",
month = "1",
day = "22",
doi = "10.1080/14656566.2017.1282462",
language = "English",
volume = "18",
pages = "205--216",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Pharmacotherapy for treating metastatic clear cell renal cell carcinoma

AU - Porta, Camillo

AU - Chiellino, Silvia

AU - Ferrari, Alessandra

AU - Mariucci, Sara

AU - Liguigli, Wanda

PY - 2017/1/22

Y1 - 2017/1/22

N2 - Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which benefited very few patients, at the expenses of high toxicities) to the present era of targeted agents and novel immunotherapeutics, greatly improving the prognosis of our patients. Areas covered: Here we have reviewed the present status of the medical treatment of metastatic RCC. To do this, we interrogated the Medline database, as well as the proceedings of the main Oncological and Urological conferences for the relevant trials coducted so far. Expert opinion: Despite all the advances made in these relatively few years, further improvements are needed, since none of the available agents proved able to cure even a sigle metastatic RCC patient. In particular, advances are awaited from the results of ongoing trial of combinations of different immune checkpoint inhibitors and of immune checkpoint inhibitors with anti-VEGF/VEGFRs agents. Furthermore, a better understanding of the molecular escape pathways used by the tumor to overcome VEGFR blockade or immune activation will hopefully bring soon to the clinic more active, tailored treatments, to be used in second line and beyond.

AB - Introduction: Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which benefited very few patients, at the expenses of high toxicities) to the present era of targeted agents and novel immunotherapeutics, greatly improving the prognosis of our patients. Areas covered: Here we have reviewed the present status of the medical treatment of metastatic RCC. To do this, we interrogated the Medline database, as well as the proceedings of the main Oncological and Urological conferences for the relevant trials coducted so far. Expert opinion: Despite all the advances made in these relatively few years, further improvements are needed, since none of the available agents proved able to cure even a sigle metastatic RCC patient. In particular, advances are awaited from the results of ongoing trial of combinations of different immune checkpoint inhibitors and of immune checkpoint inhibitors with anti-VEGF/VEGFRs agents. Furthermore, a better understanding of the molecular escape pathways used by the tumor to overcome VEGFR blockade or immune activation will hopefully bring soon to the clinic more active, tailored treatments, to be used in second line and beyond.

KW - Clear cell renal cell carcinoma

KW - immune checkpoint inhibitors

KW - metastatic disease

KW - mTOR inhibitors

KW - pharmacotherapy

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85011695798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011695798&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1282462

DO - 10.1080/14656566.2017.1282462

M3 - Review article

C2 - 28103447

AN - SCOPUS:85011695798

VL - 18

SP - 205

EP - 216

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -